Your browser is no longer supported. Please, upgrade your browser.
MEIP [NASD]
MEI Pharma, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own0.57% Shs Outstand112.68M Perf Week-8.40%
Market Cap289.71M Forward P/E- EPS next Y-0.42 Insider Trans0.00% Shs Float112.07M Perf Month-8.76%
Income-60.40M PEG- EPS next Q-0.20 Inst Own71.20% Short Float5.89% Perf Quarter-19.93%
Sales35.10M P/S8.25 EPS this Y11.00% Inst Trans- Short Ratio4.28 Perf Half Y-16.12%
Book/sh0.28 P/B8.18 EPS next Y34.40% ROA-32.60% Target Price10.89 Perf Year-24.17%
Cash/sh1.15 P/C1.99 EPS next 5Y-0.10% ROE-126.00% 52W Range2.28 - 4.57 Perf YTD-14.23%
Dividend- P/FCF- EPS past 5Y5.80% ROI-168.30% 52W High-49.95% Beta1.35
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin97.40% 52W Low0.44% ATR0.15
Employees76 Current Ratio5.50 Sales Q/Q252.60% Oper. Margin- RSI (14)38.52 Volatility5.38% 5.61%
OptionableYes Debt/Eq0.00 EPS Q/Q-466.50% Profit Margin- Rel Volume0.46 Prev Close2.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.54M Price2.29
Recom1.80 SMA20-9.63% SMA50-14.21% SMA200-20.57% Volume0 Change0.00%
Sep-22-20Initiated Alliance Global Partners Buy $9
May-29-20Initiated SunTrust Buy $16
Dec-20-18Initiated H.C. Wainwright Buy $10
Dec-20-18Initiated H.C. Wainwright Buy
Jul-27-18Upgrade Stifel Hold → Buy $2.50 → $7
Jul-13-18Initiated SunTrust Buy $12
Apr-18-16Reiterated Wedbush Neutral $3 → $2
Mar-23-15Downgrade ROTH Capital Buy → Neutral $14 → $2.50
Dec-18-14Reiterated ROTH Capital Buy $22 → $14
Oct-16-14Reiterated ROTH Capital Buy $20 → $22
Jul-08-14Resumed Brean Capital Buy $16
Oct-22-13Reiterated Stifel Buy $11 → $15
Apr-15-13Initiated Stifel Buy $11
Jan-15-22 08:50AM  
Jan-03-22 04:01PM  
Dec-06-21 04:00PM  
Dec-03-21 04:00PM  
Dec-01-21 08:46PM  
12:56PM  
10:19AM  
08:44AM  
Nov-30-21 04:00PM  
07:00AM  
Nov-29-21 04:00PM  
Nov-23-21 08:00AM  
Nov-10-21 06:35PM  
04:05PM  
08:00AM  
Nov-04-21 09:00AM  
Nov-02-21 03:02PM  
Nov-01-21 04:01PM  
Oct-22-21 10:46AM  
Oct-06-21 11:21AM  
Oct-01-21 04:00PM  
Sep-22-21 08:00AM  
Sep-07-21 09:03AM  
Sep-03-21 04:05PM  
Sep-02-21 05:45PM  
04:05PM  
08:00AM  
Aug-26-21 08:00AM  
Aug-18-21 10:36AM  
Aug-17-21 08:00AM  
Aug-05-21 04:01PM  
Aug-02-21 04:01PM  
Jul-29-21 05:54PM  
Jul-16-21 05:10AM  
Jul-07-21 08:00AM  
Jul-01-21 04:01PM  
Jun-09-21 06:00AM  
Jun-07-21 08:00AM  
Jun-04-21 08:00AM  
May-19-21 05:00PM  
May-12-21 10:00AM  
04:42AM  
May-06-21 06:55PM  
04:05PM  
Apr-30-21 09:00AM  
Apr-29-21 05:06PM  
Apr-13-21 07:00AM  
Apr-12-21 12:53PM  
Apr-10-21 08:30AM  
Apr-05-21 08:00AM  
Mar-12-21 10:50PM  
Mar-10-21 04:30PM  
Mar-02-21 08:00AM  
Feb-11-21 12:02AM  
Feb-05-21 10:50PM  
Feb-04-21 05:35PM  
04:05PM  
Jan-28-21 12:32PM  
Jan-14-21 02:45AM  
Jan-04-21 07:00AM  
Dec-18-20 10:50PM  
Dec-15-20 08:40PM  
Nov-15-20 09:20AM  
Nov-10-20 04:05PM  
Nov-09-20 08:00AM  
Oct-30-20 11:03AM  
Oct-23-20 06:22PM  
04:50PM  
Oct-12-20 10:52AM  
Oct-09-20 06:20PM  
02:00PM  
02:00PM  
11:56AM  
11:00AM  
09:19AM  
Oct-08-20 07:29PM  
11:45AM  
11:00AM  
09:26AM  
Oct-07-20 01:45PM  
10:00AM  
09:47AM  
Oct-06-20 09:44AM  
Oct-05-20 05:45PM  
04:48PM  
11:00AM  
09:30AM  
Oct-02-20 05:09PM  
10:00AM  
09:42AM  
07:00AM  
Sep-30-20 09:00PM  
01:25PM  
11:45AM  
11:00AM  
Sep-28-20 08:47PM  
01:00PM  
Sep-26-20 10:48PM  
Sep-25-20 12:33PM  
Sep-24-20 03:18PM  
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLD DANIEL P PHDChief Executive OfficerMay 25Option Exercise2.525,00012,600458,632May 27 01:35 PM
DRISCOLL FREDERICK WDirectorFeb 23Sale4.0325,000100,62537,500Feb 24 12:08 PM